Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357. - Taiwo BO; Zheng Y; Rodriguez K; Burke L; Reeves JD; Scarsi KK; Gama L; Petropoulos CJ; Belaunzaran-Zamudio PF; Wannamaker P; D'Amico R; Rathod P; et al. (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026)